Vaccine HEXAXIM (6000) at Dr. Essa Lab

Vaccine HEXAXIM (6000) at Dr. Essa Lab

Vaccine HEXAXIM (6000) is a premier, fully liquid hexavalent combination vaccine designed to protect infants and toddlers against six major infectious diseases in a single, convenient injection. Administered at Dr. Essa Lab, this advanced vaccine represents a significant milestone in preventive pediatric medicine. It combines antigens for diphtheria, tetanus, pertussis (acellular), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib). By consolidating these critical immunizations into one formulation, Vaccine HEXAXIM (6000) minimizes the number of injections a child must receive, significantly reducing physical discomfort, parental anxiety, and the number of clinic visits required to complete the primary pediatric immunization schedule.

The technology behind Vaccine HEXAXIM (6000) is highly sophisticated. Unlike older generation vaccines that required manual reconstitution of the Hib component with a liquid suspension of other antigens immediately before administration, Hexaxim is supplied as a fully liquid, ready-to-use suspension. This eliminates preparation steps, minimizes the risk of dosing or reconstitution errors by healthcare providers, and ensures consistent potency and sterility. The vaccine utilizes acellular pertussis (aP) components, which contain only purified, specific proteins of the Bordetella pertussis bacterium rather than the whole killed bacterium. This clinical refinement drastically reduces the incidence of common post-vaccination side effects, such as high-grade fever, localized swelling, and prolonged crying, while maintaining robust protective efficacy.

At Dr. Essa Lab, a premier diagnostic and preventive healthcare institution in Karachi, Pakistan, the administration of Vaccine HEXAXIM (6000) is conducted under strict clinical protocols. Maintaining the vaccine cold chain is paramount; Dr. Essa Lab utilizes state-of-the-art medical refrigeration and continuous temperature monitoring systems to ensure that the vaccine is stored precisely between 2°C and 8°C from the moment of receipt to the exact second of administration. This meticulous attention to detail guarantees that the immunogenic integrity of each antigen is fully preserved, providing infants with the maximum possible immunological defense against these life-threatening childhood pathogens.

Clinical Procedure: What to Expect

Patient Preparation

Preparing an infant or toddler for the Vaccine HEXAXIM (6000) at Dr. Essa Lab involves several simple but critical steps to ensure clinical safety and a comfortable experience for both the child and the parents:

• Vaccination Record: Always bring the child’s official vaccination card or immunization booklet. The pediatric nurse at Dr. Essa Lab will review the child’s complete immunization history to confirm the correct dosing schedule and interval.
• Health Assessment: Ensure the child is in good general health on the day of vaccination. If the child has a mild cold, minor runny nose, or low-grade fever, the vaccine can usually still be administered safely. However, if the child is suffering from a moderate to severe acute illness or a high-grade fever, it is clinically advisable to postpone the vaccination until they recover.
• Feeding Guidelines: Feed the infant lightly about 30 to 45 minutes before the appointment. Avoid overfeeding immediately prior to the injection to minimize the risk of spitting up or vomiting due to crying or temporary distress.
• Comfortable Clothing: Dress the infant in loose, comfortable clothing that allows easy access to the anterolateral aspect of the thigh (the vastus lateralis muscle), which is the clinically preferred site for intramuscular injection in infants.
• Allergy Disclosure: Inform the healthcare provider of any known medical conditions, history of seizures, bleeding disorders, or previous allergic reactions to any vaccine component.

During the Procedure

The administration of Vaccine HEXAXIM (6000) at Dr. Essa Lab is performed by highly trained pediatric nursing professionals who specialize in gentle, swift, and clinically precise immunization techniques:

• Positioning: The parent or guardian will be asked to hold the infant securely in their lap. The nurse will guide the parent on how to hold the child’s arms and legs gently but firmly to prevent sudden movements during the injection.
• Site Preparation: The nurse will identify the injection site on the anterolateral aspect of the middle third of the thigh. The skin is thoroughly cleansed with a sterile alcohol swab and allowed to air dry completely to prevent stinging.
• Administration: The nurse will gently pinch the muscle tissue and insert the fine-gauge needle at a 90-degree angle into the vastus lateralis muscle. The fully liquid Vaccine HEXAXIM (6000) is injected slowly and steadily. The entire injection process takes less than five seconds.
• Immediate Post-Care: A sterile cotton ball or gauze pad is applied to the injection site with light pressure for a few seconds to prevent minor bleeding, followed by the application of a small, child-friendly adhesive bandage.
• Observation Period: After the injection, the parent and child are advised to remain in the comfortable waiting area at Dr. Essa Lab for approximately 15 to 30 minutes. This standard clinical observation period ensures immediate medical assistance is available in the extremely rare event of an acute allergic reaction (anaphylaxis).

When is a Vaccine HEXAXIM (6000) Performed?

Primary Pediatric Immunization Schedule

Vaccine HEXAXIM (6000) is primarily administered during infancy as part of the routine primary immunization series. Pediatricians and international health organizations, including the World Health Organization (WHO), recommend administering this hexavalent vaccine at specific intervals—typically at 6, 10, and 14 weeks of age, or at 2, 4, and 6 months of age. This structured schedule is designed to build early, robust immunity during the first year of life when infants are most vulnerable to severe, life-threatening bacterial and viral infections.

Prevention of Diphtheria, Tetanus, and Pertussis

Physicians prescribe Vaccine HEXAXIM (6000) to establish early protection against three severe bacterial diseases. Diphtheria causes a thick membrane to form in the throat, leading to severe airway obstruction and systemic toxin-mediated organ damage. Tetanus, contracted through environmental spores entering wounds, causes painful, life-threatening muscle spasms and lockjaw. Pertussis, or whooping cough, leads to violent, uncontrollable coughing fits that can cause severe hypoxia, apnea, and pneumonia in infants. This vaccine stimulates the production of specific neutralizing antibodies against these bacterial toxins and antigens.

Immunization Against Hepatitis B Virus

Hepatitis B is a highly contagious viral infection that attacks the liver and can cause both acute and chronic disease. Infants who contract Hepatitis B are at an extremely high risk—up to 90%—of developing chronic, lifelong liver infections, which can eventually lead to progressive liver cirrhosis, liver failure, or hepatocellular carcinoma (liver cancer) later in life. Administering Vaccine HEXAXIM (6000) ensures early, highly effective active immunization against the Hepatitis B virus, protecting the child from horizontal transmission and potential environmental exposure.

Poliomyelitis Eradication and Defense

Poliomyelitis is a highly infectious viral disease that invades the nervous system and can cause irreversible flaccid paralysis or death within a matter of hours. In regions where polio eradication efforts are ongoing, maintaining high population immunity is critical. Vaccine HEXAXIM (6000) contains Inactivated Poliovirus (IPV) strains (Types 1, 2, and 3). IPV is highly effective and completely eliminates the risk of vaccine-associated paralytic poliomyelitis (VAPP), which was a rare but serious concern associated with the older oral polio vaccines (OPV).

Prevention of Invasive Haemophilus Influenzae Type B Infections

Haemophilus influenzae type b (Hib) is a bacterium responsible for severe, invasive childhood infections, including bacterial meningitis, epiglottitis, osteomyelitis, and severe pneumonia. Hib meningitis can lead to permanent neurological damage, hearing loss, or death. Because infants under the age of two do not naturally produce a strong immune response to the polysaccharide capsule of the Hib bacterium, Vaccine HEXAXIM (6000) utilizes a conjugated vaccine technology where the Hib polysaccharide is chemically linked to a tetanus protein carrier, enabling the infant’s immature immune system to mount a powerful and lasting protective response.

What Does a Vaccine HEXAXIM (6000) Detect?

As an active immunizing agent rather than a diagnostic test, Vaccine HEXAXIM (6000) does not detect active disease. Instead, it introduces specific, highly purified, non-infectious antigenic components into the body to stimulate, train, and evaluate the immune system’s protective capabilities. The administration of this vaccine targets and triggers specific physiological, immunological, and clinical parameters, which include:

• Diphtheria Toxoid Antigen: Stimulates the production of specific neutralizing IgG antibodies against the Corynebacterium diphtheriae toxin.
• Tetanus Toxoid Antigen: Induces high titers of protective antibodies against the neurotoxin produced by Clostridium tetani.
• Pertussis Toxoid (PT): Promotes targeted antibody responses against the primary virulence factor of Bordetella pertussis.
• Filamentous Haemagglutinin (FHA): Triggers antibodies that block the adherence of pertussis bacteria to respiratory epithelial cells.
• Hepatitis B Surface Antigen (HBsAg): Stimulates the synthesis of protective anti-HBs antibodies, preventing viral entry into hepatocytes.
• Inactivated Poliovirus Type 1 (Mahoney Strain): Induces systemic neutralizing antibodies to block Type 1 poliovirus replication in neural tissues.
• Inactivated Poliovirus Type 2 (MEF-1 Strain): Promotes robust immunological defense against Type 2 poliovirus.
• Inactivated Poliovirus Type 3 (Saukett Strain): Ensures complete seroconversion and protection against Type 3 poliovirus.
• Polyribosylribitol Phosphate (PRP): Provides the essential polysaccharide antigen required for targeted immunity against the Hib capsule.
• Tetanus Protein Conjugation Carrier: Facilitates T-cell dependent immune processing, ensuring long-term immunological memory in young infants.
• Humoral Immune Activation: Triggers the proliferation of antigen-specific B-lymphocytes within the regional lymph nodes.
• Immunological Memory B-Cells: Establishes a long-lived pool of memory cells that respond rapidly upon future exposure to wild pathogens.
• Helper T-Cell (CD4+) Stimulation: Activates helper T-cells to coordinate a balanced and durable immune response.
• Seroconversion Verification: Enables the clinical achievement of protective antibody titers (e.g., anti-HBs >= 10 mIU/mL) post-series completion.
• Systemic Antibody Circulation: Ensures the widespread distribution of protective IgG antibodies throughout the bloodstream and mucosal surfaces.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the administration of Vaccine HEXAXIM (6000) is documented immediately to ensure seamless continuity of care. Upon successful administration of the vaccine, the pediatric nurse will instantly update your child’s physical vaccination card, noting the exact date of administration, the vaccine brand name, the manufacturer, the specific batch/lot number, and the scheduled date for the next booster or subsequent vaccine dose. This physical record is vital for school admissions, international travel, and routine pediatric consultations.

In addition to the physical card, Dr. Essa Lab utilizes an advanced electronic medical records (EMR) system. The details of the vaccination are logged into the secure digital database immediately. Parents can access their child’s complete immunization history and diagnostic reports online through the Dr. Essa Lab web portal or by downloading the official Dr. Essa Lab mobile application. This digital access ensures that your child’s vital health records are safely backed up and accessible from anywhere in the world, at any time.

Vaccine HEXAXIM (6000) Findings Overview

The following table outlines the clinical parameters, expected normal physiological responses, and potential abnormal findings associated with the administration of Vaccine HEXAXIM (6000):

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Diphtheria Antibody Titer	Seroprotective antibody level (>= 0.1 IU/mL) achieved after primary series.	Inadequate antibody response (sub-protective level < 0.1 IU/mL).
Tetanus Antibody Titer	Seroprotective antibody level (>= 0.1 IU/mL) ensuring systemic protection.	Blunted immune response requiring clinical evaluation or additional booster.
Anti-HBs Antibody Level	Protective titer (>= 10 mIU/mL) demonstrating active immunity to Hepatitis B.	Non-responder status (anti-HBs < 10 mIU/mL) after complete series.
Poliovirus Neutralizing Antibodies	Presence of neutralizing antibodies against Poliovirus Types 1, 2, and 3.	Absence of protective neutralizing antibodies to one or more strains.
Anti-PRP (Hib) Antibody Level	Long-term protective titer (>= 1.0 ug/mL) or short-term protection (>= 0.15 ug/mL).	Insufficient antibody levels, leaving the child susceptible to invasive Hib.
Injection Site Reaction	Mild, transient redness, slight swelling, or localized tenderness resolving within 48 hours.	Severe localized swelling (> 5 cm), persistent erythema, or sterile abscess formation.
Post-Vaccination Temperature	Normal body temperature or transient low-grade fever (< 38.5°C) resolving quickly.	High-grade fever (> 39.0°C) or febrile seizures requiring immediate medical care.
Systemic Behavioral Response	Mild, temporary irritability or slight drowsiness that resolves with rest.	Inconsolable, persistent high-pitched crying lasting for 3 hours or more.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine HEXAXIM (6000)?

• Experienced Healthcare Professionals: Dr. Essa Lab employs highly skilled, gentle, and compassionate pediatric nurses who specialize in administering childhood immunizations with minimal discomfort.
• Uncompromised Cold Chain Integrity: We utilize advanced, continuous temperature-monitored refrigeration systems to ensure that Vaccine HEXAXIM (6000) maintains maximum potency and safety.
• Established Legacy of Trust: Founded in 1987 by Prof. Dr. Essa M. Abdulla, Dr. Essa Lab is one of Pakistan’s most respected diagnostic and preventive healthcare networks.
• Convenient Digital Access: Parents can easily access, download, and track their child’s complete immunization records via our secure online portal and mobile application.
• Child-Friendly Environment: Our dedicated vaccination clinics are designed to be warm, welcoming, and stress-free for infants, toddlers, and parents alike.
• Rigorous Quality Standards: Dr. Essa Lab operates under strict international quality control protocols, ensuring that all diagnostic and preventive services meet global benchmarks.
• Comprehensive Diagnostic Integration: From routine pediatric blood tests to advanced imaging, Dr. Essa Lab offers a complete spectrum of healthcare services under one roof.
• Widespread Accessibility: With numerous branches conveniently located across Karachi and other major cities, accessing premium healthcare and vaccination services is always simple.